Somatostatin analogs inhibit neonatal retinal neovascularization
Related Experiment Video
Updated: Sep 20, 2026
Whole Mount Immunofluorescent Staining of the Neonatal Mouse Retina to Investigate Angiogenesis In vivo
Published on: July 9, 2013
Rosemary D Higgins1, Yun Yan, Bruce K Schrier
1Department of Pediatrics, Division of Neonatology, Georgetown University Children's Medical Center, 3800 Reservoir Road, NW M3400, Washington, DC, 20007, USA. higginsr1@gunet.georgetown.edu
Abstract:
The goal of this study was to determine the effect of two somatostatin analogs, Woc4D and octreotide, on oxygen induced retinopathy in the mouse. Oxygen induced retinopathy was produced in C57BL6 mice. Octreotide and Woc4D were administered from post-natal day 12-16. Retinopathy was assessed by a retinal scoring system utilizing fluorescein perfused retinal whole mounts. Animals treated with Woc4D and octreotide, respectively, had median retinopathy scores of 4(3,5) [median(25th, 75th quartile)] with P = 0.01 and 3.5(2.9,4.3) with P = 0.01 compared to oxygen and sham treated oxygen animals with scores of 6.6(5.3,8.5) and 7.4(5.8,8.6), respectively. Woc4D and octreotide treated animals had decreased blood vessel tufts and decreased extra-retinal neovascularization when compared to oxygen treated animals. Pituitary growth hormone (GH) mRNA expression was increased 8.3-fold by Woc4D treatment and 106-fold by oxygen exposure, and GH and mRNA was markedly reduced by Woc4D as well as octreotide. Growth as measured by animal weight was unaffected by either treatment. Woc4D and octreotide inhibited retinal neovascularization in an equally effective manner in the mouse model of oxygen induced retinopathy.
Insights
Two somatostatin analogs, Woc4D and octreotide, effectively inhibited oxygen-induced retinopathy in mice by reducing retinal neovascularization. These compounds offer a promising therapeutic strategy for retinopathy, a condition affecting blood vessel growth in the eye.
Area of Science:
- Ophthalmology
- Vascular Biology
- Pharmacology
Background:
- Oxygen-induced retinopathy (OIR) is a common animal model for neovascular eye diseases.
- Retinal neovascularization is a hallmark of OIR and contributes to vision loss.
- Somatostatin analogs are being investigated for their potential therapeutic effects in various conditions.
Purpose of the Study:
- To evaluate the efficacy of two somatostatin analogs, Woc4D and octreotide, in a mouse model of oxygen-induced retinopathy.
- To assess the impact of these analogs on retinal neovascularization and related molecular markers.
Main Methods:
- Oxygen-induced retinopathy was established in C57BL6 mice.
- Woc4D and octreotide were administered daily from postnatal day 12 to 16.
- Retinopathy was quantified using a scoring system on fluorescein-perfused retinal whole mounts.
- Pituitary growth hormone (GH) mRNA expression was measured.
Main Results:
- Both Woc4D and octreotide significantly reduced retinopathy scores compared to control groups (P = 0.01).
- Treated animals exhibited decreased blood vessel tufts and reduced extra-retinal neovascularization.
- Woc4D and octreotide treatments markedly reduced elevated pituitary growth hormone (GH) mRNA expression.
Conclusions:
- Woc4D and octreotide demonstrate potent inhibitory effects on retinal neovascularization in the OIR mouse model.
- These somatostatin analogs represent a potential therapeutic avenue for managing neovascular eye diseases.
- Further research is warranted to explore the clinical applications of these compounds in retinopathy treatment.
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...